Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT06996730RecruitingPhase 2/Phase 3
Study of donanemab and RG6289 for genetic Alzheimer's disease
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
Medellín, AntioquiaAges 25–65 - NCT06992804RecruitingEarly Phase 1
Light therapy and lecanemab for mild Alzheimer's
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
BeijingAges 50–90 - NCT06965062Recruiting
Neck surgery for Alzheimer's: a first test
This study tests a new surgery called cervical lymphatic bypass to see if it can help people with Alzheimer's disease. The surgery creates a new connection in the neck to improve drainage of waste from the brain, which may slow memory loss.
SingaporeAges 50–80 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT06869135Recruiting
Saliva testing for brain diseases
This trial is collecting saliva samples from people with Alzheimer's, Parkinson's, or other brain diseases to find new ways to diagnose them. It may help improve early detection.
Florence, FIAges 45 years+ - NCT06860828Enrolling by invitation
Football players and brain health study: DIAGNOSE CTE
This study looks at brain changes in former college and professional football players, people with memory problems, and healthy controls. It aims to learn more about chronic traumatic encephalopathy (CTE) and Alzheimer's disease.
Phoenix, ArizonaAges 50 years+ - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Phoenix, ArizonaAges 55–80 - NCT06179680Recruiting
White matter changes in memory problems or Alzheimer's
This study uses brain MRI scans to look at white matter changes in people with memory problems (amnestic mild cognitive impairment) or Alzheimer's disease. It aims to understand how these changes relate to memory loss.
San Donato Milanese, MilanoAges 65 years+ - NCT06826157Enrolling by invitation
Brain Wave Patterns in Early Memory Loss and Dementia
This study uses an advanced EEG (electroencephalogram) to measure brain wave activity in people with early Alzheimer's, frontotemporal dementia, or Lewy body dementia. It aims to find patterns that could help doctors better understand the disease and predict how it might progress.
Milan, ItalyAges 50–85 - NCT06761066Enrolling by invitation
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
SeoulAges 60 years+ - NCT06741553Recruiting
Studying lecanemab for early Alzheimer's disease
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hangzhou, ZhejiangAges Up to 85 years - NCT06731842Enrolling by invitation
Brain scans and blood tests for Alzheimer's disease
This study uses a special brain scan (PET imaging) and blood tests to look for early signs of Alzheimer's and other brain diseases. It aims to improve how we detect and understand these conditions.
StockholmAges 30–85 - NCT06723015Enrolling by invitationPhase 2
Tau PET in anti-amyloid therapy for Alzheimer's
This study uses brain scans to see how anti-amyloid treatments affect tau protein buildup in people with early Alzheimer's. If you have mild cognitive impairment or mild Alzheimer's, you may be eligible to help understand how these treatments work.
Rochester, MinnesotaAges 50–90 - NCT06703541Recruiting
Alzheimer's disease research study with brain scans and spinal tap
This study at Duke University is looking for people aged 25 to 80 who may be at risk for Alzheimer's disease. It involves brain scans (MRI and PET) and a spinal tap to learn more about the disease and find better ways to detect and treat it early.
Durham, North CarolinaAges 25–80 - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06639282RecruitingPhase 2
Testing siponimod for mild Alzheimer's dementia
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
Phoenix, ArizonaAges 50–85 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06597942RecruitingPhase 1/Phase 2
Brain stimulation for Alzheimer's disease
This study tests whether a new type of brain stimulation (called repetitive transcranial magnetic stimulation, or rTMS) with a larger coil can improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves multiple sessions of rTMS and MRI scans.
Los Angeles, CaliforniaAges 55–100 - NCT06548191RecruitingPhase 1
Time-Restricted Eating for Alzheimer's Disease
This study tests whether a time-restricted eating schedule (eating all meals within a 10-hour window each day) can improve memory and thinking in people with early Alzheimer's disease or mild cognitive impairment. Healthy partners of people with memory problems can also join as a comparison group.
San Diego, CaliforniaAges 60 years+ - NCT06538311RecruitingEarly Phase 1
TMS treatment for early Alzheimer's disease
This study tests whether a non-invasive brain stimulation treatment called TMS (transcranial magnetic stimulation) can help people with early Alzheimer's disease or related memory problems. It's a safe, gentle way to stimulate brain cells using magnetic pulses.
Boston, MassachusettsAges 40–99 - NCT06489548RecruitingPhase 2
Foralumab for Early Alzheimer's Disease
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
Boston, MassachusettsAges 60–85 - NCT06484244Recruiting
Walking and balance in memory loss
This study looks at how older adults with mild cognitive impairment or Alzheimer's disease adapt their walking. It aims to understand walking and balance to help people stay mobile and safe longer.
Atlanta, GeorgiaAges 50–90 - NCT06448403Recruiting
Alzheimer's assessment study with brain scans
This study uses brain scans (MRI and EEG) to better understand Alzheimer's disease. It compares people with MCI or Alzheimer's to healthy volunteers to see how the disease affects the brain.
Trondheim, TrønderlagAges 65 years+
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 305 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.